Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3NUMH)

Drug Name
Aripiprazole Drug Info
Synonyms
129722-12-9; Abilify; Abilitat; Abilify Discmelt; OPC-14597; Discmelt; Opc 14597; OPC 31; OPC-31; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril; UNII-82VFR53I78; C23H27Cl2N3O2; HSDB 7320; 7-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE; CHEMBL1112; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone; CHEBI:31236; Abilify; Aripiprazol; Aripiprazolum; Aripirazole; Arpizol; Asprito; Pripiprazole; Aripiprazole [USAN]; Otsuka brand of aripiprazole; OPC 14597; ALKS-9070; Abilify (TN); BMS-337039; Bristol-Myers Squibb brand of aripiprazole; Discmelt (TN); KS-1030; S06-0010; Aripiprazole (JAN/USAN/INN); 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril; 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; ALKS9070/ALKS9072; Aripiprazole/escitalopram fixed-dose combination
Indication
Disease Entry ICD 11 Status REF
Bipolar I disorder Approved [1]
Erythropoietic porphyrias 5C58.12 Approved [2]
Schizoaffective disorder 6A21 Approved [1]
Schizophrenia 6A20 Approved [3]
Major depressive disorder 6A70.3 Phase 3 [4]
Bipolar disorder 6A60 Application submitted [5]
Autism Investigative [1]
Therapeutic Class
Antipsychotic Agents
Cross-matching ID
PubChem CID
60795
ChEBI ID
CHEMBL31236
CAS Number
CAS 129722-12-9
TTD Drug ID
DM3NUMH
VARIDT Drug ID
DR00766
INTEDE Drug ID
DR0136
ACDINA Drug ID
D00043

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Dopamine D2 receptor (D2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [12]
Haloperidol DM96SE0 Delirium Approved [13]
Perphenazine DMA4MRX Schizophrenia 6A20 Approved [14]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [15]
Domperidone DMBDPY0 Gastrointestinal disease DE2Z Approved [16]
Levodopa DMN3E57 Parkinson disease 8A00.0 Approved [17]
Quetiapine DM1N62C Anorexia nervosa cachexia 6B80 Approved [18]
Pimozide DMW83TP Schizophrenia 6A20 Approved [19]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [20]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [22]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [23]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [24]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [25]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [26]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [27]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [28]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [29]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [23]
Verapamil DMA7PEW Angina pectoris BA40 Approved [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [31]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [32]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [33]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [26]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [30]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [34]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [35]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [36]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [37]
Propranolol DM79NTF Angina pectoris BA40 Approved [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [39]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [40]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [41]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [8]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [42]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [43]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [44]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [45]
Verapamil DMA7PEW Angina pectoris BA40 Approved [46]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [47]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [8]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [8]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [8]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [48]
Verapamil DMA7PEW Angina pectoris BA40 Approved [49]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [8]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [8]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [8]
Metronidazole DMTIVEN Abscess Approved [50]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By G antigen 1 (GAGE1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [51]
Drug(s) Affected By Sodium-dependent serotonin transporter (SLC6A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Paroxetine DM5PVQE Anxiety disorder 6B00-6B0Z Approved [52]
Fluoxetine DM3PD2C Bipolar depression Approved [53]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [54]
Ribavirin DMEYLH9 Hepatitis C virus infection 1E51.1 Approved [55]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [56]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [57]
Quercetin DM3NC4M Obesity 5B81 Approved [58]
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [56]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [59]
Mepyramine DMB4SFH Allergic rhinitis CA08.0 Approved [60]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cancer/testis antigen 1 (CTAG1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [61]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [62]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [63]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [64]
Drug(s) Affected By Interferon-stimulated gene 20 kDa protein (ISG20)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [65]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [66]
Methylprednisolone DM4BDON Acute adrenal insufficiency Approved [65]
Testosterone DM7HUNW Hot flushes GA30 Approved [67]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [67]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [68]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [69]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [70]
Azathioprine DMMZSXQ Lupus nephritis 4A40.0Y Approved [65]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [62]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Fasciculation and elongation protein zeta-1 (FEZ1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [71]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [72]
Panobinostat DM58WKG Chronic graft versus host disease Approved [73]
Testosterone enanthate DMB6871 N. A. N. A. Approved [74]
Tubocurarine DMBZIVP Anaesthesia 9A78.6 Approved [75]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [76]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [77]
Mecamylamine DMGQFYB Essential hypertension BA00 Approved [75]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [78]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [70]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Synaptotagmin-17 (SYT17)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [79]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [80]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [61]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [81]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [82]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [83]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [73]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [84]
THAPSIGARGIN DMDMQIE N. A. N. A. Preclinical [85]
COUMESTROL DM40TBU Discovery agent N.A. Investigative [86]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Nucleotide-binding oligomerization domain-containing protein 2 (NOD2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [87]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [88]
Testosterone DM7HUNW Hot flushes GA30 Approved [89]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [90]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [80]
Menthol DMG2KW7 Back pain ME84.Z Approved [91]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [62]
Arsenic DMTL2Y1 N. A. N. A. Approved [92]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [93]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [94]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 5-hydroxytryptamine receptor 2A (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [95]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [96]
Paliperidone DM7NPJS Psychotic disorder 6A20-6A25 Approved [97]
Haloperidol DM96SE0 Delirium Approved [97]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [61]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [70]
Olanzapine DMPFN6Y Bipolar depression Approved [98]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [99]
Arsenic DMTL2Y1 N. A. N. A. Approved [100]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [101]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [7]
Cytochrome P450 2D6 (CYP2D6) Main DME DECB0K3 CP2D6_HUMAN Substrate [7]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [8]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
5-hydroxytryptamine receptor 2A (HTR2A) OTWXJX0M 5HT2A_HUMAN Drug Response [9]
Cancer/testis antigen 1 (CTAG1B) OTIQGW6U CTG1B_HUMAN Gene/Protein Processing [10]
Fasciculation and elongation protein zeta-1 (FEZ1) OTWCXPRE FEZ1_HUMAN Gene/Protein Processing [10]
G antigen 1 (GAGE1) OT53E50E GAGE1_HUMAN Gene/Protein Processing [10]
Interferon-stimulated gene 20 kDa protein (ISG20) OTCWRJJW ISG20_HUMAN Gene/Protein Processing [10]
Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) OTPGYWKC NOD2_HUMAN Gene/Protein Processing [10]
Sodium-dependent serotonin transporter (SLC6A4) OT6FGDLW SC6A4_HUMAN Protein Interaction/Cellular Processes [11]
Synaptotagmin-17 (SYT17) OTTW4MI3 SYT17_HUMAN Gene/Protein Processing [10]

References

1 Aripiprazole FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 34).
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034267)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5.
7 Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.
8 Drug Interactions Flockhart Table
9 Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J. 2006 Jan-Feb;6(1):42-51. doi: 10.1038/sj.tpj.6500342.
10 Small Molecule Antipsychotic Aripiprazole Potentiates Ozone-Induced Inflammation in Airway Epithelium. Chem Res Toxicol. 2019 Oct 21;32(10):1997-2005. doi: 10.1021/acs.chemrestox.9b00149. Epub 2019 Sep 11.
11 Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter. J Med Chem. 2011 Sep 22;54(18):6305-18. doi: 10.1021/jm200682b. Epub 2011 Aug 23.
12 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
13 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
14 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
15 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
16 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
18 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
19 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
20 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
21 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
22 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
23 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
24 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
25 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
26 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
27 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
28 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
29 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
30 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
31 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
32 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
33 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
34 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
35 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
36 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
37 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
38 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
39 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
40 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
41 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
42 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
43 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
44 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
45 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
46 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
47 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
48 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
49 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
50 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
51 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
52 Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett. 2005 Nov 25;389(1):12-6. doi: 10.1016/j.neulet.2005.06.048.
53 Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol. 2003 Dec;6(4):339-46. doi: 10.1017/S1461145703003663.
54 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
55 Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand J Immunol. 2006 Feb;63(2):106-15. doi: 10.1111/j.1365-3083.2005.01715.x.
56 Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18. doi: 10.1016/j.toxlet.2021.10.013. Epub 2021 Nov 5.
57 Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res. 2005 Feb 28;133(2-3):197-203. doi: 10.1016/j.psychres.2004.11.005.
58 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
59 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
60 GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND). J Med Chem. 2002 Apr 11;45(8):1577-84. doi: 10.1021/jm011007+.
61 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
62 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
63 Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells. J Neurooncol. 2009 Mar;92(1):15-22. doi: 10.1007/s11060-008-9732-0. Epub 2008 Nov 22.
64 Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
65 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
66 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
67 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
68 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
69 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
70 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
71 Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
72 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
73 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
74 Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
75 Nicotine modulates the expression of a diverse set of genes in the neuronal SH-SY5Y cell line. J Biol Chem. 2003 May 2;278(18):15633-40.
76 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
77 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
78 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
79 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
80 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
81 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
82 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
83 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
84 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
85 Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
86 Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
87 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
88 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
89 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
90 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
91 Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
92 Fetal-sex dependent genomic responses in the circulating lymphocytes of arsenic-exposed pregnant women in New Hampshire. Reprod Toxicol. 2017 Oct;73:184-195. doi: 10.1016/j.reprotox.2017.07.023. Epub 2017 Aug 6.
93 NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease. Am J Gastroenterol. 2008 May;103(5):1197-202. doi: 10.1111/j.1572-0241.2007.01741.x. Epub 2008 Mar 26.
94 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
95 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
96 Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
97 Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.
98 No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
99 Nephrotoxicity induced by cisplatin is primarily due to the activation of the 5-hydroxytryptamine degradation system in proximal renal tubules. Chem Biol Interact. 2021 Nov 1;349:109662. doi: 10.1016/j.cbi.2021.109662. Epub 2021 Sep 21.
100 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
101 Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod. 2011 Jul;26(7):1813-25.